



LEADER IN GENE SILENCING TECHNOLOGY

18 February 2004

NEWS

Promega Corporation Sub-licensed Chemicon International

Benitec (ASX:BLT) is pleased to announce that its global partner and licensee, Promega Corporation (Madison, Wisconsin), has sub-licensed Chemicon International, Inc (Temecula, CA and the research division of Serologicals Corporation, NASDAQ/NM:SERO) to develop and sell products and reagents for life science products based on Benitec's ddRNAi technology.

John McKinley, Benitec's Chairman and CEO, stated..." Promega's announcement of the sub-license to Chemicon confirms the importance being attached to Benitec's ddRNAi technology by leaders in RNAi product development. Chemicon's additional expertise will support Promega in providing the diverse range of ddRNAi products now required by a rapidly growing global customer base. Weekly publications further attest to the growing RNAi researchers' recognition of the many advantages of Benitec's ddRNAi technology in research activities and in the future development of therapies, the ultimate goal for RNAi development and Benitec's core focus."

About Benitec Limited

Benitec Limited, based in Queensland, was the first company to recognise and demonstrate the effect of ddRNAi in mammalian and human cells and has the world's only patents issued covering this discovery. This natural mechanism is now recognised worldwide as the simplest and most precise method for shutting down the activity of any specific gene. The technology is immediately applicable to functional genomics and the identification and validation of drug targets and, following internal project work and third party collaborations, it is evident that this technology can also be applied to the treatment of major human diseases such as cancers, autoimmune disorders and viral infections by shutting down or suppressing the disease-causative genes. Benitec offers customers licences to use ddRNAi in the human field and is building a proprietary ddRNAi clinical development program initially targeting HIV and certain cancers.

This press release contains forward-looking statements which reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

CONTACTS

John McKinley
Chairman & CEO
+44 7767 367 193
+61 7 3217 8540
jmckinley@benitec.com.au

Promega Corporation
Richard Schifreen
608-277-2473
Rich.Schifreen@promega.com



NEWS

Serologicals' Research Division, Chemicon International, Inc. and Promega Corporation Enter into an Agreement for DNA-directed RNAi Product Development and Applications

TEMECULA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Feb. 17, 2004--
CHEMICON International, Inc. ("Chemicon"), a division of Serologicals Corporation (NASDAQ/NM: SERO), and Promega Corporation ("Promega") today announced that Chemicon has entered into a sub-license agreement with Promega for the use and application of DNA-directed, RNA interference ("ddRNAi") technology. Promega is the exclusive global licensee in certain fields for the proprietary ddRNAi technology from Benitec Ltd. of Queensland, Australia. Under the terms of the agreement, Chemicon will have the right to use the technology to develop and sell ddRNAi-based products and reagents for life science research. Promega will also provide Chemicon with proprietary materials that will support Chemicon's development of enabling products for the study of the role of genes in mammalian physiology. The financial terms of the agreement were not disclosed.

"This agreement represents a significant expansion of our efforts in functional genomics. Through the licensing of the ddRNAi technology, Chemicon now has the opportunity to provide a comprehensive portfolio of RNAi-based products and reagents to the research community," said Jeffrey D. Linton, President of Chemicon.

William Linton, Promega President and CEO stated: "We are delighted to execute a sub-license with Chemicon that will help expand the value and market for this important new technology. Promega is looking forward to a close working relationship with Chemicon and helping to make these tools widely available to the research community."

About Promega Corporation

Promega Corporation is a global leader in providing innovative solutions for the life sciences industry. The company's 1,200 products enable scientists worldwide to advance knowledge in cellular analysis, proteomics, and genomics research with applications in drug discovery, molecular diagnostics, and human identification. Founded in 1978, the company is headquartered in Madison, Wisconsin, USA, and has extensive international distribution. For more information about Promega, visit www.promega.com.

- MORE-

About Serologicals and Chemicon

Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. Customers include many of the leading research institutions and life science companies throughout the world. The Company's products and technologies are used in a wide variety of innovative applications within the areas of neurobiology, cell signaling, cancer, angiogenesis, apoptosis, developmental biology, cellular physiology, oncology, hematology, immunology, cardiology, infectious diseases, and molecular biology. Through its Chemicon Division, the Company also manufactures diagnostic products at its cGMP, ISO, and TGA approved facilities. Chemicon International, Inc., a wholly owned subsidiary of Serologicals Corporation, is headquartered in Temecula, California. Serologicals has more than 650 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. Serologicals is a registered trademark of Serologicals Royalty Company. For more information on Serologicals Corporation and Chemicon International, visit the companies' web sites at www.serologicals.com and www.chemicon.com.

Serologicals is a registered trademark of Serologicals Royalty Company.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. These risks and uncertainties include, without limitation, the value of the licensed research tools and the utility of the licensed research tools to researchers. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release.

CONTACT:

Serologicals Corporation, Atlanta
Chemicon International, Inc.
Patrick Schneider, 909-676-8080, ext. 308
pschneider@chemicon.com

or

Promega Corporation
Richard Schifreen, 608-277-2473
Rich.Schifreen@promega.com